Kristen Williams - 21 Mar 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Chief Administrative Officer
Signature
/s/ Kristen Williams
Issuer symbol
PCRX
Transactions as of
21 Mar 2022
Net transactions value
-$217,613
Form type
4
Filing time
23 Mar 2022, 16:37:20 UTC
Previous filing
01 Mar 2022
Next filing
08 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Options Exercise $113,248 +2,953 +13% $38.35 25,221 21 Mar 2022 Direct F1
transaction PCRX Common Stock Options Exercise $91,956 +2,112 +8.4% $43.54 27,333 21 Mar 2022 Direct F1
transaction PCRX Common Stock Options Exercise $104,258 +2,188 +8% $47.65 29,521 21 Mar 2022 Direct F1
transaction PCRX Common Stock Sale $527,076 -7,253 -25% $72.67 22,268 21 Mar 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -2,953 -50% $0.000000 2,953 21 Mar 2022 Common Stock 2,953 $38.35 Direct F2
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -2,112 -17% $0.000000 10,560 21 Mar 2022 Common Stock 2,112 $43.54 Direct F2
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -2,188 -10% $0.000000 19,685 21 Mar 2022 Common Stock 2,188 $47.65 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2 The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.